Umbilical & Placental Cell News
IL-33-Activated ILC2s Induce Tertiary Lymphoid Structures in Pancreatic Cancer
[Nature] In mice, IL-33 deficiency severely attenuated inflammation- and lymphotoxin (LT)–LTβ receptor-activation-induced tertiary lymphoid structures in models of colitis and PDAC.
Elucidating the Role of Pyrimidine Metabolism in Prostate Cancer and Its Therapeutic Implications
[Scientific Reports] Through transcriptomic and single-cell RNA sequencing analyses, researchers explored metabolic pathway enrichment, immune infiltration patterns, and differential gene expression in prostate cancer samples.
Ontario First in Canada to Administer New Publicly Funded Prostate Cancer Care Treatment
[Ontario Newsroom] The Ontario government is connecting more people to care by being the first Canadian jurisdiction to publicly fund and administer PLUVICTO™ a new treatment for advanced-stage prostate cancer, which is now covered under the province’s publicly funded drug program.
Capture Primed Pluripotency in Guinea Pig
[Stem Cell Reports] Scientists isolated and characterized guinea pig epiblast stem cells from post-implantation embryos. These cells differentiated into the three germ layers, maintained normal karyotypes, and relied on FGF2 and ACTIVIN A signaling for self-renewal and pluripotency.
Combining Top-Down and Bottom-Up: An Open Microfluidic Microtumor Model for Investigating Tumor Cell-ECM Interaction and Anti-Metastasis
[Small] The Under-oil Open Microfluidic System microtumor model – allowing a controlled but also self-organized, cell-directed tumor-ECM microenvironment in an open microfluidic configuration – was used to test an anti-metastasis drug with a triple-negative breast cancer cell line.
Precision Medicine for High-Risk Gene Fusions in Pediatric AML: A Focus on KMT2A, NUP98, and GLIS2 Rearrangements
[Blood] The authors discuss the current molecular landscape and functional characterization of three of the most lethal childhood AML fusion-oncogene driven subtypes harboring KMT2A, NUP98, or CBFA2T3::GLIS2 rearrangements.
ADARp110 Promotes Hepatocellular Carcinoma Progression via Stabilization of CD24 mRNA
[Proceedings of The National Academy of Sciences of The United States of America] Scientists investigated the role of ADARp110 in hepatocellular carcinoma and underlying mechanisms using clinical samples, a hepatocyte-specific Adarp110 knock-in mouse model, and engineered cell lines.
PLAC8 Attenuates Pulmonary Fibrosis and Inhibits Apoptosis of Alveolar Epithelial Cells via Facilitating Autophagy
[Communications Biology] The authors found that PLAC8 was downregulated in the lungs of idopathic pulmonary fibrosis patients, in bleomycin-induced lungs of mice, and in primary murine alveolar epithelial type II cells and human lung epithelial cell A549 cells.
Patient-Derived Cornea Organoid Model to Study Metabolomic Characterization of Rare Disease: Aniridia-Associated Keratopathy
[BMC Ophthalmology] Corneal organoids were generated from hiPSCs derived from aniridia patients with three different paired-box gene 6 nonsense mutations, allowing for a detailed comparison between diseased and healthy control models.
In Vivo Base Editing Extends Lifespan of a Humanized Mouse Model of Prion Disease
[Nature Medicine] Investigators developed in vivo cytosine and adenine base strategies delivered by adeno-associated viruses to permanently modify the PRNP locus to achieve prion protein knockdown in the mouse brain.
Specification of Claustro-Amygdalar and Palaeocortical Neurons and Circuits
[Nature] Scientists revealed that the transcription factors SOX4, SOX11 and TFAP2D had a pivotal role in the development, identity, and prefrontal cortex connectivity of ventrolateral pallial neurons.
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
[Eisai Co., Ltd.] Eisai Co., Ltd. and Biogen Inc.announced that the US FDA has accepted Eisai’s Biologics License Application for lecanemab-irmb subcutaneous autoinjector for weekly maintenance dosing.